Revvity has announced the development of the T-SPOT A201, a next-generation high-throughput automated platform designed to support the performance advantages of T-SPOT.TB testing for large-volume clinical laboratories, enabling a reliable, accurate solution for latent tuberculosis (TB) detection.
Tuberculosis remains a critical global health challenge, with testing demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and broader public health programs. It is crucial for laboratories to deliver accurate results upon initial testing, while managing a high volume of samples to support timely treatment and improved patient outcomes.
Building on the success of the Auto-Pure 2400 liquid handler, (pictured) the T-SPOT A201 platform is engineered to meet the throughput requirements of large-scale testing environments, strengthening the Revvity’s automation portfolio and its ability to support laboratories across a range of throughput needs. It can process up to 384 samples per instrument in an 8-hour shift, with 45 seconds per sample of hands-on time – the lowest of any T-SPOT automation solution. The platform aims to ensure that these laboratories benefit from the scalability and workflow advantages associated with automated T-SPOT.TB testing.
"The T-SPOT A201 automation platform represents a significant step forward in making the benefits of T-SPOT.TB testing accessible at scale," said Steven Hart, Vice President and General Manager of Infectious Disease Diagnostics at Revvity. "Our development program is focused on delivering a solution that gives high-volume clinical laboratories the performance, workflow efficiency, and competitive economics they need."
The T-SPOT A201 platform is currently under development and targeted for launch in the second half of 2027, subject to regulatory approval.